Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO,…
-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO,…
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company…
Orphazyme A/S in restructuringCompany announcement No. 19/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, April…
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3…
New York, NY, and Tel Aviv, ISRAEL, April 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire —Todos…
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be…
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”),…
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the…
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader…
SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional…
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology…
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…
ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…
LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc…
– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for…
Topline data anticipated in late Q3/early Q4 A total of 432 subjects are enrolled in…